Histogen Inc. financial data

Industry
Pharmaceutical Preparations
Location
10655 Sorrento Valley Road, Suite 200, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Conatus Pharmaceuticals Inc. (to 5/21/2020), Conatus Pharmaceuticals Inc (to 6/23/2014)
Latest financial report
10-Q - Q3 2023 - Nov 9, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 773 % -24%
Debt-to-equity 44.7 % +28.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.27M shares 0%
Common Stock, Shares, Outstanding 4.27M shares 0%
Entity Public Float 5.4M USD -87.4%
Common Stock, Value, Issued 5K USD 0%
Weighted Average Number of Shares Outstanding, Basic 4.27M shares +20.2%
Weighted Average Number of Shares Outstanding, Diluted 4.27M shares +20.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 19K USD -99.5%
Research and Development Expense 3.28M USD -40.8%
General and Administrative Expense 8.8M USD -2.71%
Operating Income (Loss) -12.1M USD -11.5%
Income Tax Expense (Benefit) 0 USD
Earnings Per Share, Basic -2.83 USD/shares +10.9%
Earnings Per Share, Diluted -2.83 USD/shares +10.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.57M USD -68.6%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 40K USD -57%
Assets, Current 5.46M USD -66.6%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 4.49M USD -6.73%
Other Assets, Noncurrent 362K USD -43.3%
Assets 5.82M USD -73.8%
Accounts Payable, Current 386K USD -31.2%
Employee-related Liabilities, Current 787K USD +443%
Accrued Liabilities, Current 943K USD +59%
Liabilities, Current 1.35M USD -3.58%
Operating Lease, Liability, Noncurrent 4.24M USD -5.88%
Liabilities 1.41M USD -76.2%
Retained Earnings (Accumulated Deficit) -97.7M USD -14.5%
Stockholders' Equity Attributable to Parent 5.44M USD -68.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 4.4M USD -72.9%
Liabilities and Equity 5.82M USD -73.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.55M USD -639%
Net Cash Provided by (Used in) Financing Activities -2K USD +99.6%
Net Cash Provided by (Used in) Investing Activities -15K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 4.27M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.55M USD -205%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.87M USD -67.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1K USD -75%
Deferred Tax Assets, Valuation Allowance 24.7M USD +7.98%
Deferred Tax Assets, Gross 25.7M USD +6.67%
Operating Lease, Liability 4.5M USD -4.5%
Payments to Acquire Property, Plant, and Equipment 15K USD
Lessee, Operating Lease, Liability, to be Paid 7.21M USD -9.63%
Property, Plant and Equipment, Gross 1.2M USD -0.41%
Operating Lease, Liability, Current 265K USD +25%
Lessee, Operating Lease, Liability, to be Paid, Year Two 827K USD +2.99%
Lessee, Operating Lease, Liability, to be Paid, Year One 803K USD +2.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.7M USD -17.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 853K USD +3.14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 816K USD +19.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 879K USD +3.05%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 978K USD -18.4%
Share-based Payment Arrangement, Expense 534K USD +18.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%